News

ONS is developing a collection of photos of dermatologic toxicities across skin types to address disparities in the care of patients of color with cancer.

Claire Conley, PhD, and Marcelo Sleiman, Jr., discuss the need for protocols in supporting patients’ psychosocial needs.

Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer had improved rPFS with capivasertib plus abiraterone.

Zongertinib has been granted accelerated approval in NSCLC harboring HER2 TKD mutations as part of the Commissioner’s National Priority Voucher pilot program.

The FDA has approved encorafenib plus cetuximab and fluorouracil-based chemotherapy in patients with BRAF V600E-positive metastatic colorectal cancer.

Of 9 evaluable patients with progressive non–small cell lung cancer (NSCLC) and progressive SCLC, 6 achieved disease control with Olvi-Vec.

What is the role of oncology nurses as artificial intelligence technologies become a clinical reality?

The FDA has approved acalabrutinib plus venetoclax in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

WVU Medicine has begun treating patients in the first clinical trial to explore the use of subcutaneous blinatumomab in patients with CD19-positive MPAL.

Emely Alfaro, RN, MSN, CNS, OCN, shares exclusive insights on her cancer-specific research on patients with difficult IV access.

The FDA has approved a monthly dosing schedule for subcutaneous amivantamab in NSCLC following the first 4 weeks of treatment.

A device delivering tumor treating fields has been approved for concurrent treatment with gemcitabine and nab-paclitaxel for patients with LA-PAC.

Emese Zsiros, MD, PhD, FACOG, discusses managing paclitaxel toxicity and the role of pembrolizumab maintenance in treating platinum-resistant ovarian cancer.

Patients with NRG1 fusion-positive cholangiocarcinoma who received zenocutuzumab had a favorable response rate in the phase 1/2 eNRGy trial.

David C. Leopold, MD, explains how evidence-based integrative therapies like acupuncture and nutrition improve oncology patient outcomes and compliance.

New clinical data highlight the impact of infusion timing on NSCLC survival, alongside updated ASCO guidelines and FDA RMAT status for inhaled KB707.

The FDA approved IV and subcutaneous pembrolizumab with paclitaxel with or without bevacizumab for patients with platinum-resistant ovarian cancers.

In a clip from the latest Onc Nurse on Call episode, social worker Kelly Grosklags explains that emotions strengthen the connection between patient and clinician in oncology.

Practical examples of advanced practice provider–led initiatives that improve safety, symptom management, and patient outcomes.

The FDA updated its safety labeling for capecitabine and 5-FU to reflect that patients with certain genetic variants risk severe or fatal toxicities.

Investigator Elizabeth Lee, MD, discusses efficacy and safety data for rinatabart sesutecan in patients with endometrial cancer.

A look at the current state of cancer, from survival rates to federal research budgets.

Kelly Grosklags, LICSW, BCD, FAAGC, FT, shares advice for dealing with grief in oncology nursing, from treating patients in denial to showing emotion in front of them.

Dato-DXd has been given priority review for the treatment of patients with unresectable/metastatic triple-negative breast cancer.

Multicancer early detection tests may expand screening options, but does the benefit outweigh the uncertainties?

In a world of unfamiliarity and uncertainty, patient advocates help guide those with cancer through challenging diagnoses and the decisions that come with them.

Nurses are called to honor Alex Pretti’s memory through compassion and action.

The FDA approved a larger vial size of nelarabine for the treatment of pediatric and adult patients with T-ALL and T-LBL.